Home › Trials › NCT07119970

Using NETosis blood markers to predict clot risk in JAK2-positive myeloproliferative neoplasms

Prospective Study for the Evaluation of the Prognostic Value of NETosis Markers to Predict Thrombosis in Myeloproliferative Neoplasms With JAK2V617F Mutation (AVATARE)

Not applicable Interventional University Hospital, Bordeaux · NCT07119970

This study will try to see if blood markers of NETosis can predict clotting risk in people with JAK2V617F-positive myeloproliferative neoplasms who are at high risk for thrombosis.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment300 (estimated)
Ages18 Years and up
SexAll
SponsorUniversity Hospital, Bordeaux Academic / other
Locations15 sites (Angers and 14 other locations)
Trial IDNCT07119970 on ClinicalTrials.gov

What this trial studies

This ancillary study enrolls JAK2V617F-positive patients with polycythemia vera, essential thrombocythemia, or pre-myelofibrosis who are high risk for thrombosis and already taking part in the AVAJAK trial. Participants will have blood drawn at baseline and at 12 months to measure NETosis markers such as calprotectin and citrullinated histone H3 (H3Cit). Marker levels will be correlated with subsequent thrombotic events to test whether NETosis biomarkers improve prediction beyond age and prior thrombosis. The goal is to determine whether these measurements can guide safer, more personalized thrombosis prevention strategies.

Who should consider this trial

Good fit: Ideal candidates are adults with a recent diagnosis (within 12 months) of PV, ET, or pre-MF who are JAK2V617F-positive with allelic burden >1%, meet high-risk criteria (age >60 or prior thrombosis), are enrolled in the AVAJAK trial and the FIMBANK biobank, and can give informed consent.

Not a fit: Patients without a JAK2V617F mutation, those at low thrombotic risk, those on heparin at inclusion, or patients with severe renal or hepatic failure are unlikely to benefit from this biomarker-based prognostic approach.

Why it matters

Potential benefit: If successful, the approach could improve prediction of who will get blood clots and help tailor prevention so fewer patients are over- or undertreated.

How similar studies have performed: Prior studies have shown increased NETs in MPN patients and links between NETosis and thrombosis, and aspirin can reduce NET formation, but prospective use of NETosis markers as a clinical prognostic tool remains relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Diagnosis of Polycythemia Vera (PV), Essential Thrombocythemia (ET), or pre-myelofibrosis (pre-MF)
* JAK2V617F mutation with an allelic burden greater than 1%
* High risk of thrombosis (age over 60 years or prior thrombotic event)
* Diagnosis of MPN within the last 12 months
* Enrollment in the AVAJAK clinical trial and the FIMBANK biobank
* Affiliation with social security
* Signed informed consent

Exclusion Criteria:

* Severe hepatic or renal insufficiency (Creatinine clearance \<30ml/min)
* Patients under legal protection (guardianship or curatorship)
* Patients under heparin treatment at inclusion

Where this trial is running

Angers and 14 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Myeloproliferative NeoplasmMyeloproliferative DisordersMyeloproliferative neoplasmsThrombosisNeutrophil extracellular trapsNeutrophils
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.